Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma

Ishihara, Hiroki; Tachibana, Hidekazu; Takagi, Toshio; Kondo, Tsunenori; Fukuda, Hironori; Yoshida, Kazuhiko; Iizuka, Junpei; Kobayashi, Hirohito; Okumi, Masayoshi; Ishida, Hideyuki; Tanabe, Kazunari

doi:10.1007/s11523-019-00660-6

Cited by 57 publications

(51 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have demonstrated their prognostic role in various types of cancers, including RCC (21,22). Moreover, higher NLR and PLR are associated with worse prognosis in immunotherapy for patients with RCC (23,24). High activity of inflammatory response is noted with elevated NLR and PLR, while chronic inflammation usually leads to tumor development by suppressing the immune system.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of peripheral blood T lymphocyte subsets in clear cell renal cell carcinoma

Zhou¹,

Jiang²,

Chu³

et al. 2021

Transl Androl Urol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of peripheral blood T lymphocyte subsets in clear cell renal cell carcinoma

Zhou¹,

Jiang²,

Chu³

et al. 2021

Transl Androl Urol

View full text Add to dashboard Cite

show abstract

“…Peng et al found that pre‐operation PNI may be a good prognostic factor for both OS and PFS in RCC patients 8 . Ishihara et al proved that NLR, LMR, and CRP were predictive factors in nivolumab therapy for mRCC 9 . However, inflammation related miRNAs had not been studied with inflammation status in peripheral blood of ccRCC patients.…”

Section: Discussionmentioning

confidence: 99%

“…Studies had indicated that inflammation status such as neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and lymphocyte‐to‐monocyte ratio (LMR) were significantly associated with outcomes of RCC patients 7,8 . LMR had a predictive role in Nivolumab therapy of mRCC 9 …”

Section: Introductionmentioning

confidence: 99%

MiR‐483‐5p downregulation contributed to cell proliferation, metastasis, and inflammation of clear cell renal cell carcinoma

Wang

Zhu

Wang

et al. 2020

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Inflammation status are especially for tumor growth, and microRNAs (miRNAs) confirmed to participate in cancer occurrence and progression. However, the role of miR‐483‐5p and the relation with inflammation have not been elucidated in renal cell cancer (RCC). In this study, we intended to explore miR‐483‐5p expression and the relationship of inflammation status in clear cell renal cell cancer (ccRCC). Using microarray and qRT‐PCR (Quantitative Real‐time Polymerase Chain Reaction), we investigated the miR‐483‐5p expression in plasma and ccRCC cancer tissues. Then, we analyzed the correlation of miR‐483‐5p with clinicopathological parameters and inflammation status in ccRCC. Receiver operator characteristic (ROC) curves analysis was used to analyze the discrimination efficiency of miR‐483‐5p. in vitro experiments explored the biological role of miR‐483‐5p in renal cancer cells. miR‐483‐5p expression was upregulated in plasma of 5 patients with microarray and 12 patients with qRT‐PCR in ccRCC at day 7 postoperatively. In addition, low expression of miR‐483‐5p was found in 58 ccRCC cancer tissues when compared with non‐cancerous tissues. miR‐483‐5p could sufficiently discriminate ccRCC with the area under the curve (AUC) of 0.739 (P < .0001) from normal tissues. Higher expression of miR‐483‐5p was positively related to lower tumor stage and higher relative expression of miR‐483‐5p was inversely related to neutrophil‐to‐lymphocyte ratio (NLR) (P = .03) and lymphocyte‐to‐monocyte ratio (LMR) (P = .026). Overexpression of miR‐483‐5p lead to reverse epithelial‐mesenchymal transition (EMT) process, restrain cell proliferation and metastasis of renal cancer cells. Our findings suggest that miR‐483‐5p expression is negatively correlation with inflammation status and may be a potential plasma biomarker for ccRCC.

show abstract

“…Second, this study could not clarify the clinical benefit of the decrease in NLR level after the treatment. We previously showed that the decrease in CRP levels is associated with improved patient survival 4 . Finally, they did not include CRP in the present study.…”

mentioning

confidence: 80%

Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma

Cited by 57 publications

References 51 publications

Prognostic value of peripheral blood T lymphocyte subsets in clear cell renal cell carcinoma

Prognostic value of peripheral blood T lymphocyte subsets in clear cell renal cell carcinoma

MiR‐483‐5p downregulation contributed to cell proliferation, metastasis, and inflammation of clear cell renal cell carcinoma

Editorial Comment to Inflammatory markers for predicting responses to nivolumab in patients with metastatic renal cell carcinoma

Contact Info

Product

Resources

About